Skip to main content

Approaches for Prioritizing High-Quality Chemical Matter in Chemical Probe and Drug Discovery

Thank you

This live event has ended. Please enjoy the recording. 

Join SLAS for more insight into selected research featured in the SLAS Discovery Special Collection: Approaches for Prioritizing High-Quality Chemical Matter in Chemical Probe and Drug Discovery.


  • Jayme L. Dahlin, M.D., Ph.D., FASCP Preclinical Medical Director, A Specialized Platform for Innovative Research Exploration (ASPIRE), National Center for Advancing Translational Sciences (NCATS)

  • Samuel Hoare, Ph.D., Founder, Pharmechanics, LLC

    Founder, Pharmechanics, a pharmacology data analysis company. Pharmacologist with 15 years experience in the pharmaceutical industry. I develop new analysis methods for drug discovery, including residence time measurement, biosensor kinetics, and biased agonism assessment. I am known for applying the residence time concept to the development of CRF receptor antagonists, and for knowledge of Class B GPCR pharmacology and drug discovery.

  • Kathryn Nelson, Ph.D., Scientist, Bio-Techne

    After obtaining a Ph.D. in Medicinal Chemistry from the University of Minnesota, Dr. Nelson was a postdoctoral associate before becoming a Research Assistant Professor in Medicinal Chemistry at the Institute for Therapeutics Discovery and Development (ITDD). Her work has focused on target discovery, validation, and lead molecule development for new targets in neurodegenerative diseases. She also expanded her expertise to the development of biomarker assays for new targets in anticipation of preclinical evaluation. Dr. Nelson is currently a Scientist in the Luminex Assay Development group at Bio-Techne in Minneapolis

September 16, 2021
Thu 10:00 AM EDT

Duration 1H 0M

This live web event has ended.

Support Contact
+1.630.256.7527 x102